Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | CA4 | P22748 | 1/20 | 0.41 |
| ▸ | SLC18A3 | Q16572 | 2/20 | 0.34 |
| ▸ | CTDSP1 | Q9GZU7 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.32 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23191939 | 1.00 | CA1 (0.41) | CA1CA2CA4SLC18A3CTDSP1 | |
| SCHEMBL12477685 | 1.00 | CA1 (0.41) | CA1CA2CA4SLC18A3CTDSP1 | |
| SCHEMBL12684669 | 1.00 | CA1 (0.41) | CA1CA2CA4SLC18A3CTDSP1 | |
| SCHEMBL15355816 | 1.00 | CA1 (0.41) | CA1CA2CA4SLC18A3CTDSP1 | |
| SCHEMBL12167102 | 1.00 | CA1 (0.41) | CA1CA2CA4SLC18A3CTDSP1 | |
| SCHEMBL13767450 | 0.97 | CA1 (0.46) | CA1CA2CA4SLC18A3CTDSP1 | |
| SCHEMBL3038819 | 0.97 | CA1 (0.46) | CA1CA2CA4SLC18A3CTDSP1 | |
| SCHEMBL21757863 | 0.97 | CA1 (0.46) | CA1CA2CA4SLC18A3CTDSP1 | |
| SCHEMBL8161261 | 0.97 | CA1 (0.46) | CA1CA2CA4SLC18A3CTDSP1 | |
| SCHEMBL712232 | 0.97 | CA1 (0.46) | CA1CA2CA4SLC18A3CTDSP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9499558-B2 | Compounds and methods for treating HIV | PURDUE RESEARCH FOUNDATION (US) | 2016-11-22 | — | — | US | disclosed |
| US-20150225414-A1 | COMPOUNDS AND METHODS FOR TREATING HIV | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-08-13 | — | — | US | disclosed |
| US-9024038-B2 | Compunds and methods for treating HIV | PURDUE RESEARCH FOUNDATION (US) | 2015-05-05 | — | — | US | disclosed |
| US-20130289067-A1 | COMPOUNDS AND METHODS FOR TREATING HIV | PURDUE RESEARCH FOUNDATION | 2013-10-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150225414-A1 | COMPOUNDS AND METHODS FOR TREATING HIV | SERPINB1, HPN, DNPEP | CA1 2022/4885CA2 3225/4885CA4 1906/4885 |
| US-20130289067-A1 | COMPOUNDS AND METHODS FOR TREATING HIV | SERPINB1, HPN, DNPEP | CA1 2022/4885CA2 3225/4885CA4 1906/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.